What is it about?
This paper summarizes the most recent results from clinical studies as well as laboratory studies on antibiotic treatment of diseases caused by nontuberculous mycobacteria.
Featured Image
Why is it important?
Reviews tend to focus on the few clinical studies and ignore the recent wealth of preclinical studies. This short editorial reviews both, to predict the future shapes of antibiotic treatment for diseases caused by nontuberculous mycobacteria.
Perspectives
Antibiotic treatment regimens for nontuberculous mycobacterial disease have never been rationally designed; they are haphazard combinations of drug that work and drugs that many hope work. Rational regimen design, combining the best and synergistic drugs will finally improve treatment outcomes. And the new generation of antibiotics that allows building such regimens are now coming into development and clinic.
Jakko van Ingen
Radboud Universiteit
Read the Original
This page is a summary of: New insights in the treatment of nontuberculous mycobacterial pulmonary disease, Future Microbiology, October 2017, Future Medicine,
DOI: 10.2217/fmb-2017-0144.
You can read the full text:
Contributors
The following have contributed to this page
